- Poster Presentations to Explore Potential of
Augmenting Resokine Pathway in Severe, Rare Pulmonary Diseases with
an Immune or Fibrotic Component -
aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged
in the discovery and development of Physiocrine-based therapeutics
to address severe, rare diseases, today announced its participation
as part of two poster presentation sessions at the upcoming
American Thoracic Society’s (ATS) 113th International Conference to
be held May 19 – 24, 2017 in Washington D.C.
In conjunction with the ATS presentations, aTyr Pharma will host
an educational webinar on Tuesday, May 23, 2017 at 8:30 a.m. ET
featuring Steven D. Nathan, M.D., FCCP, Director of the Advanced
Lung Disease Program and Medical Director of the Lung Transplant
Program at Inova Fairfax Hospital, to provide disease education on
interstitial lung diseases that are characterized by an immune or
fibrotic component. aTyr will also provide an overview of the
iMod.Fc program (Stalaris) in development for the potential
treatment of patients with severe, rare pulmonary diseases
characterized by an immune or fibrotic component for whom there are
limited treatment options. Following the presentation, Dr. Nathan
and aTyr management will be available to answer questions.
Details of the ATS poster sessions are
below:
Fibrosis: Mediators and Modulators - Tuesday, May 23,
2017
- Title: Resokine Modulates Immune Cell
Infiltration into the Lung and Provides Therapeutic Activity in a
Bleomycin-Induced Lung Fibrosis Model
- Author and Presenter: Kathy Ogilvie, PhD,
Director, Physiology, aTyr Pharma
- Supporting Authors: Do M., Chiang K., Adams
R., Crampton S., Nangle L., Cubitt A., McKew J., Ashlock M.,
Mendlein J.
- Poster Viewing: 11:15 a.m. – 1:00 p.m. ET
- Location: Area A, Hall B-C (Middle Building,
Lower Level), Walter E. Washington Convention Center
Immune Pathways in Acute Lung Injury and Fibrosis -
Wednesday, May 24, 2017
- Title: The Resokine Pathway Is
Implicated in the Pathology of Interstitial Lung Disease
- Author and Presenter: Leslie A. Nangle, PhD,
Director, Discovery Biology, aTyr Pharma
- Supporting Authors: Tong Y., Mertsching E.,
Crampton S., Adams R., Chiang K., Ogilvie K., Schimmel P., McKew
J., King D., Mendlein J.
- Poster Viewing: 9:15 a.m. – 9:45 a.m. ET
- Poster Discussion: 9:45 a.m. – 11:15
a.m. ET
- Location: Room 206 (South Building, Level 2),
Walter E. Washington Convention Center
The presentations provide early preclinical support for the
development of the iMod.Fc program for the treatment of patients
with severe, rare pulmonary diseases characterized by an immune or
fibrotic component. aTyr plans to initiate its first clinical trial
for the iMod.Fc program in the second half of the year.
Conference Call and Webcast Details
On Tuesday, May 23, 2017 at 8:30 a.m. ET, aTyr Pharma will host
a conference call and webcast with an accompanying slide
presentation to discuss interstitial lung disease and the iMod.Fc
program. The live webcast and slide presentation will be available
on the Investors page of the Company's website at
www.atyrpharma.com. Joining the aTyr Pharma management will be
Steven D. Nathan, M.D., FCCP, director of the Advanced Lung Disease
Program and medical director of the Lung Transplant Program at
Inova Fairfax Hospital.
To access the call, please dial 844-358-9116 (domestic) or
209-905-5951 (international) and ask to join the aTyr Pharma call.
A replay of the webcast will be archived on the Company’s website
following the call.
About the iMod.Fc Program
aTyr Pharma scientists successfully engineered the first fusion
protein with a Physiocrine, iMod.Fc, to provide designed properties
to enhance the immuno-modulatory aspects of a Physiocrine in
vivo. The Company is developing iMod.Fc as a potential therapeutic
for patients with rare pulmonary diseases with an immune or
fibrotic component, including interstitial lung disease. This
fusion protein, which utilizes the Fc region of an antibody, also
potentially represents a novel Fc-Physiocrine platform for future
Physiocrine-based therapies.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development
of innovative medicines for patients suffering from severe, rare
diseases using its knowledge of Physiocrine biology, a newly
discovered set of physiological pathways. To date, the Company has
generated three innovative therapeutic candidate programs based on
its knowledge of Physiocrine biology in three different therapeutic
areas. aTyr has built an intellectual property estate, to protect
its pipeline, comprising over 190 issued patents or allowed patent
applications that are owned or exclusively licensed, including over
300 potential Physiocrine-based protein compositions. aTyr's key
programs are currently focused on severe, rare diseases
characterized by immune imbalance for which there are currently
limited or no treatment options. For more information, please visit
http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act.
Forward-looking statements are usually identified by the use of
words such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,”
and variations of such words or similar expressions. We intend
these forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements, including statements
regarding the potential and potential therapeutic benefits of
iMod.Fc, the ability of the Company to successfully advance its
pipeline or product candidates, undertake certain development
activities (such as clinical trial enrollment and the conduct of
clinical trials) and accomplish certain development goals and the
timing of such activities and development goals, the timing of
initiation of additional clinical trials, the scope and strength of
our intellectual property portfolio, our ability to receive
regulatory approvals for, and commercialize, our product candidates
and of reporting results from our clinical trials reflect our
current views about our plans, intentions, expectations, strategies
and prospects, which are based on the information currently
available to us and on assumptions we have made. Although we
believe that our plans, intentions, expectations, strategies and
prospects as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, risks associated with the
discovery, development and regulation of our Physiocrine-based
product candidates, as well as those set forth in our most recent
Annual Report on Form 10-K for the year ended December 31, 2016 and
in our other SEC filings. Except as required by law, we assume no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
Mark Johnson
Sr. Director, Investor Relations
mjohnson@atyrpharma.com
858-223-1163
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2024 to May 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From May 2023 to May 2024